repurposing semaglutide and liraglutide for alcohol use disorder A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used weight loss, such as semaglutide, may also help reduce heavy drinking in individuals GLP-1 medications: The next big

2 Precise mechanisms remain unclear, but an interplay of endothelial injury, hypercoagulability, hypoxia, and immune complex deposition contributes to the formation of these sterile vegetations

plantarum reduced the abundance of Bacteroides and Parabacteroides , and also decreased the levels of lithocholic acid (LCA), eventually increasing BG (104)

Tirzepatide (Mounjaro/Zepbound): A similar drug that also shows potential for reducing cravings

to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition

appeal rights have time limits (typically 180 days) Earlier appeals processed faster Provide Additional Evidence : Clinical literature supporting treatment Documentation of health impacts from obesity Expected health improvements from weight loss Cost-effectiveness arguments (preventing future health costs) Consider Escalation : If multiple appeals denied, consider: Employer HR department involvement (for employer plans) State insurance commissioner complaint External review process Healthcare attorney consultation (for complex cases) Complete FDA Safety Information for GLP-1 Weight Loss Medications FDA Boxed Warning: Thyroid C-Cell Tumor Risk According to FDA prescribing information, ALL GLP-1 receptor agonist medications including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) carry an FDA Boxed Warning-the agency's most prominent safety warning designation